English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, April 8, 2019
Eisai to Launch Chocola BB Sparkling Kiwi & Lemon Flavor
エーザイ、「チョコラBB(R)スパークリング キウイ&レモン味」新発売
Friday, April 5, 2019
エーザイ、シリーズ初の医薬部外品「トラベルミン(R)サポート」新発売
Eisai to Launch "Travelmin Support" as Series' First Quasi-Drug
Friday, March 29, 2019
Eisai: Data Safety Monitoring Board Recommends Continuation of Phase III Clinical Studies of Bace Inhibitor Elenbecestat in Early Alzheimer's Disease
エーザイ、BACE阻害剤elenbecestatの早期アルツハイマー病を対象とした臨床第III相試験について安全性データモニタリング委員会が試験継続を推奨
Friday, March 22, 2019
Eisai's Initiation of Phase III Clinical Trial of BAN2401 in Early Alzheimer's Disease
Eisai to Present Latest Research on Alzheimer's Disease / Dementia Pipeline at the 14th International Conference on Alzheimer's & Parkinson's Diseases
エーザイ、BAN2401について早期アルツハイマー病を対象とした臨床第III相試験を開始
バイオジェンとエーザイ、アルツハイマー病を対象としたアデュカヌマブの臨床第III相国際共同試験(ENGAGE試験、EMERGE試験)を中止

Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575